IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Management believes that theIDE397 study data demonstrates important clinical proof-of-concept in MTAPdeletion solid tumors to deliver meaningful responses and encourage preliminary durability of response with a convenient 30mg once-a-day tablet. The reported clinical efficacy and tolerability data are preliminary, drawn from an investigator-reviewed unlocked database as of the cutoff date of Jun 21, 2024. Per the data readout, the study achieved an overall response rate of 39%. Among the 18 evaluable patie ...